FDA Clears MRI-Based AI Segmentation of Organs at Risk During Radiation Therapy
Capable of segmenting over 37 organs and structures in the head, neck and pelvis, the MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.
The Food and Drug Administration (FDA) has granted 510(k) clearance for MR Contour DL software, a deep learning-enabled magnetic resonance imaging (MRI) segmentation software that may facilitate enhanced radiation therapy treatment in the head, neck, and pelvis.
Currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference (May 2-6, 2025) in Vienna, Austria, the MR Contour DL software utilizes the soft tissue detail from MRI to provide artificial intelligence (AI)-powered segmentation of organs at risk, according to GE HealthCare, the developer of MR Contour DL.
Providing artificial intelligence (AI)-powered segmentation of organs at risk during radiation therapy, the newly FDA-cleared MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.
Leveraging standard 2D and 3D MRI, GE HealthCare noted the MR Contour DL software is capable of segmenting 37 organs and structures in the head, neck, and pelvis.
“We’re committed to advancing MR imaging capabilities in radiation therapy to deliver more accurate and precise care,” said Kelly Londy, the president and CEO of MR for GE HealthCare.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
